StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
22
Publishing Date
2023 - 10 - 22
1
2023 - 10 - 09
1
2023 - 09 - 22
1
2023 - 06 - 28
1
2023 - 06 - 27
1
2023 - 04 - 14
1
2023 - 03 - 21
1
2023 - 03 - 09
1
2023 - 01 - 20
1
2023 - 01 - 19
1
2022 - 12 - 15
1
2022 - 11 - 16
1
2022 - 09 - 12
1
2022 - 07 - 06
1
2022 - 06 - 27
1
2022 - 06 - 26
1
2022 - 01 - 19
1
2021 - 10 - 12
2
2021 - 09 - 22
1
2021 - 09 - 14
1
2021 - 09 - 01
1
Sector
Health technology
22
Manufacturing
22
Tags
Acquisition
4
Advanced
5
Agreement
19
Alliances
6
America
15
Antibody
6
Application
18
Approved
5
Asco
4
Asia
7
At845
5
Authorization
5
Biotech
7
Biotech-bay
7
Bladder
12
Cancer
49
Cell
7
Children
4
China
4
Chmp
4
Collaboration
15
Companies
12
Cresemba
4
Disease
16
Drug
26
Earnings
4
Events
5
Expected
4
Fda
17
Financial
4
Genetown
5
Global
27
Grants
4
Growing
6
Growth
47
Health
4
Japan
7
Leukemia
6
License
17
Management
7
Market
113
N/a
269
Padcev
11
Pharma
13
Pharmaceutical
5
Positive
14
Reach
5
Report
24
Research
43
Results
19
Set
5
Study
14
Therapeutics
35
Therapy
23
Topline
10
Treatment
50
Trial
22
Update
6
Vaccine
7
Xtandi
6
Entities
Astellas pharma inc
22
Essa pharma inc.
1
Merck & company, inc.
1
Seagen inc.
5
Symbols
ABB
72
ABBV
32
ABLZF
31
ACHV
21
AIMC
23
ALDX
32
ALPMF
22
ALPMY
22
ARQT
22
ARVL
21
ATHE
26
ATNM
25
AVXL
21
AZN
52
BGNE
23
BIVI
23
BMY
48
BTAI
25
CLSD
22
CNHI
69
CYTK
24
DVAX
23
ENLV
24
EXEL
28
FBIO
29
FDMT
21
FNCTF
66
GIC
37
GILD
23
GTES
25
HCM
22
HON
53
HZNP
35
ICLR
26
IMAB
21
IMMP
25
IMMX
23
IMUX
21
INCY
28
JCI
22
JNJ
99
LLY
116
MBRX
30
MRK
45
NVCR
22
NVO
32
NVS
25
OCGN
22
PDSB
22
PFE
47
PSTV
29
REGN
30
RGNX
27
SLS
23
SNY
165
SNYNF
120
SRNE
33
STAG
32
TAK
36
TMO
28
Exchanges
Nasdaq
22
Nyse
1
Crawled Date
2023 - 10 - 22
1
2023 - 10 - 09
1
2023 - 09 - 22
1
2023 - 06 - 28
2
2023 - 04 - 14
1
2023 - 03 - 21
1
2023 - 03 - 09
1
2023 - 01 - 20
1
2023 - 01 - 19
1
2022 - 12 - 16
1
2022 - 11 - 17
1
2022 - 09 - 12
1
2022 - 07 - 06
1
2022 - 06 - 27
2
2022 - 01 - 19
1
2021 - 10 - 12
2
2021 - 09 - 22
1
2021 - 09 - 14
1
2021 - 09 - 01
1
Crawled Time
00:00
4
06:00
1
07:00
3
08:00
2
09:00
1
12:00
1
13:00
3
13:20
1
14:00
2
15:20
1
16:20
1
22:00
1
23:00
1
Source
www.biospace.com
8
www.prnewswire.com
14
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
symbols :
Alpmy
save search
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
Published:
2023-10-22
(Crawled : 16:20)
- prnewswire.com
ALPMF
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
Email alert
Add to watchlist
ev-302
padcev
bladder
cancer
trial
Bipolar Disorder Landscape Report with DLI's Clinical Trial Assessment, Product Portfolio Extension, and Post Launch Services | Disease Landscape Insights
Published:
2023-10-09
(Crawled : 14:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-31.47%
|
O:
-0.04%
H:
0.77%
C:
0.7%
disease
services
report
trial
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published:
2023-09-22
(Crawled : 09:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-34.73%
|
O:
-0.56%
H:
1.48%
C:
1.12%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
10.83%
|
O:
3.59%
H:
0.09%
C:
-0.05%
ev-302
padcev
bladder
cancer
trial
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published:
2023-06-28
(Crawled : 08:00)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-37.82%
|
O:
1.2%
H:
0.26%
C:
-0.2%
positive
treatment
topline
trial
results
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published:
2023-06-27
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-37.82%
|
O:
1.2%
H:
0.26%
C:
-0.2%
positive
treatment
topline
trial
results
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
Published:
2023-04-14
(Crawled : 23:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
Email alert
Add to watchlist
ALPMF
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
lancet
trial
results
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
Published:
2023-03-21
(Crawled : 22:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-33.14%
|
O:
0.57%
H:
1.35%
C:
0.43%
glow
asco
positive
trial
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib
Published:
2023-03-09
(Crawled : 07:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-33.66%
|
O:
0.36%
H:
0.14%
C:
-0.99%
topline
trial
results
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease
Published:
2023-01-20
(Crawled : 07:00)
- prnewswire.com
ALPMF
|
$9.594
43.47%
2.2K
|
Health Technology
|
-37.62%
|
O:
-1.43%
H:
0.0%
C:
0.0%
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-38.06%
|
O:
-0.07%
H:
1.33%
C:
1.26%
at845
treatment
fda
disease
lifted
trial
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium
Published:
2023-01-19
(Crawled : 15:20)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-38.23%
|
O:
0.2%
H:
0.0%
C:
-0.46%
symposium
trial
asco
positive
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
Published:
2022-12-15
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-40.01%
|
O:
1.61%
H:
0.0%
C:
-1.14%
treatment
glow
trial
her2-
her2
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
Published:
2022-11-16
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-36.51%
|
O:
1.56%
H:
0.0%
C:
-1.41%
treatment
trial
her2-
her2
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
Published:
2022-09-12
(Crawled : 13:20)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-34.13%
|
O:
0.71%
H:
0.14%
C:
-1.05%
MRK
|
$125.23
-0.11%
-0.54%
3.4M
|
Health Technology
|
43.54%
|
O:
0.9%
H:
1.17%
C:
0.03%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
47.13%
|
O:
0.12%
H:
0.0%
C:
-3.57%
padcev
trial
results
cancer
Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials
Published:
2022-07-06
(Crawled : 13:00)
- biospace.com/
ALPMF
|
$9.594
43.47%
2.2K
|
Health Technology
|
-36.55%
|
O:
2.63%
H:
0.0%
C:
0.0%
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-40.13%
|
O:
0.58%
H:
1.66%
C:
0.38%
trials
zenith
cancer
trial
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published:
2022-06-27
(Crawled : 08:00)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-42.36%
|
O:
-1.2%
H:
0.0%
C:
-0.37%
at845
fda
disease
trial
update
Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease
Published:
2022-06-26
(Crawled : 00:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-42.36%
|
O:
-1.2%
H:
0.0%
C:
-0.37%
at845
fda
disease
trial
update
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Published:
2022-01-19
(Crawled : 13:00)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-44.04%
|
O:
-0.27%
H:
0.51%
C:
0.21%
EPIX
|
$6.72
-4.95%
-6.0%
36K
|
Health Technology
|
-17.08%
|
O:
-5.58%
H:
5.2%
C:
-1.65%
epi-7386
prostate cancer
trial
phase 1
cancer
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published:
2021-10-12
(Crawled : 13:00)
- biospace.com/
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-45.96%
|
O:
2.57%
H:
0.0%
C:
-2.82%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
41.07%
|
O:
0.22%
H:
2.27%
C:
1.35%
treatment
cancer
trial
enroll
Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published:
2021-10-12
(Crawled : 12:00)
- prnewswire.com
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
-45.96%
|
O:
2.57%
H:
0.0%
C:
-2.82%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
41.07%
|
O:
0.22%
H:
2.27%
C:
1.35%
treatment
cancer
trial
enroll
Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting
Published:
2021-09-22
(Crawled : 14:00)
- biospace.com/
ALPMF
|
$9.594
43.47%
2.2K
|
Health Technology
|
Email alert
Add to watchlist
ALPMY
|
$9.46
-1.11%
500K
|
Manufacturing
|
Email alert
Add to watchlist
phase 3
trial
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$1.45
5.84%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.421
97.65%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.509
23.81%
45.26%
90K
|
GDHG
|
$0.263
21.76%
40.66%
3.1M
|
XPON
|
News
|
$3.15
63.21%
37.74%
16M
|
TIRX
|
$0.8
65.02%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.